FDA Initiates Class II Recall of Apipharma's Hemopropin Ointment Over CGMP Deviations from Croatian Facility
Apipharma faces an FDA Class II recall for 4,218 boxes of Hemopropin Ointment, citing Current Good Manufacturing Practice (CGMP) deviations at its Zagreb, Croatia facility. This action, initiated by the firm, highlights critical quality control failures, posing significant supply chain and regulatory compliance challenges for global procurement and regulatory affairs teams sourcing similar topical formulations.
FDA-Mandated Recall: Apipharma's Hemopropin Ointment Pulled Over CGMP Deviations
The U.S. Food and Drug Administration (FDA) has classified a firm-initiated recall of Apipharma's Hemopropin Ointment as Class II, signaling a significant regulatory action stemming from Current Good Manufacturing Practice (CGMP) deviations. This classification indicates that the product's use or exposure may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. For procurement directors and supply chain VPs, this classification demands immediate attention, as it directly impacts product availability and necessitates a reassessment of supplier reliability. The recall, identified as D-0375-2025, was initiated by Apipharma on April 9, 2025, with the FDA center classification occurring on April 18, 2025, and the report date being April 30, 2025. The affected product, Hemopropin Ointment, contains Lanolin 17.76% and Petrolatum 71.2%, packaged in Net Wt. 0.7 oz (20g) tubes. A substantial quantity of 4,218 boxes is subject to this recall, impacting specific lots: A00001 (Exp.: 2027-12), A00005 (Exp.: 2027-01), and B00001 (Exp.: 2028-02). This event underscores the critical importance of stringent quality control throughout the manufacturing process, as CGMP deviations can lead to widespread product withdrawals and significant commercial disruption. Businesses relying on Apipharma or similar manufacturers for topical formulations must now evaluate their contingency plans and supplier qualification processes.
Apipharma's Product and Operational Footprint in Croatia
Apipharma d.o.o., based in Zagreb, Croatia, is the manufacturer of the recalled Hemopropin Ointment, with its distribution handled by Apipharma, LLC in Tempe, Arizona. This operational structure highlights a common model where foreign manufacturers leverage U.S.-based entities for market access, yet remain subject to FDA oversight regarding product quality and manufacturing standards. For regulatory affairs heads, this emphasizes the need for comprehensive understanding of international regulatory frameworks and the FDA's jurisdiction over products imported into the U.S., regardless of the manufacturing origin. The product itself, Hemopropin Ointment, is a topical formulation with key active ingredients Lanolin (17.76%) and Petrolatum (71.2%). These are common emollients and protective agents in dermatological and over-the-counter drug products. The specific UPCs associated with the recalled product are 3 858882 103534 and 3 858882 101318, providing precise identifiers for supply chain management and inventory control. The distribution pattern is noted as 'AZ,' indicating a focused presence within Arizona. This localized distribution, while not global in scope for this specific recall, still requires immediate action from distributors and pharmacies in the region. Business development executives should note the implications for market entry strategies for foreign-manufactured products, recognizing that robust quality systems are paramount for sustained U.S. market presence.
Commercial Implications for Procurement and Supply Chain Resilience
The ongoing Class II recall of Apipharma's Hemopropin Ointment carries direct commercial implications for procurement and supply chain functions across the chemical and life sciences industry. With 4,218 boxes of product being removed from the market, businesses involved in the distribution or sale of this specific ointment, particularly in Arizona, face immediate inventory write-offs, potential revenue loss, and the operational burden of managing product returns. For procurement directors, this event underscores the financial risks associated with supplier non-compliance and the necessity of robust supplier qualification processes that extend beyond initial audits to continuous monitoring of quality systems. The recall initiated by the firm, though voluntary, is a direct consequence of identified CGMP deviations, suggesting systemic issues within Apipharma's manufacturing processes in Zagreb, Croatia. This situation demands that supply chain VPs evaluate their risk mitigation strategies, including diversifying supplier bases and establishing contingency plans for critical raw materials or finished products. The absence of detailed alternative supplier information in the public domain for this specific product means companies must proactively identify and qualify new sources for Lanolin and Petrolatum-based topical formulations, a process that can be time-consuming and costly. Furthermore, the reputational damage to Apipharma could indirectly affect other companies associated with its supply chain, necessitating clear communication strategies to maintain customer trust.
Navigating the Broader Regulatory Environment and Compliance Imperatives
This FDA Class II recall of Apipharma's Hemopropin Ointment serves as a stark reminder of the FDA's unwavering commitment to enforcing Current Good Manufacturing Practices globally, even for manufacturers located outside the United States. For regulatory affairs heads, this event reinforces the imperative of maintaining an ironclad quality management system that is continuously audited and updated to meet evolving regulatory expectations. CGMP deviations, as cited in this recall, are not merely administrative oversights; they represent fundamental failures in ensuring product quality, safety, and efficacy, which can lead to significant public health risks and severe regulatory penalties. The ongoing status of the recall (D-0375-2025) means that Apipharma will be under intense scrutiny, potentially facing further regulatory actions if remediation efforts are deemed insufficient. This incident aligns with a broader trend of heightened regulatory vigilance, exemplified by other recent actions such as the FDA's Class II recall of Essential Wellness Pharma's Progesterone Injection due to sterility assurance failures. While distinct events, they collectively highlight the critical importance of robust quality control in pharmaceutical manufacturing. Businesses must invest in comprehensive regulatory intelligence to anticipate and respond to such events, ensuring that their supply chains are resilient against similar disruptions. Proactive engagement with regulatory guidelines and continuous internal and external audits are no longer optional but essential for maintaining market access and avoiding costly recalls.